Current Health News Briefs: Key Updates from Pharma Acquisitions to Bird Flu Spread

This material provides a summary of recent health news, including a dismissed lawsuit against Bayer's Roundup, extreme heat's impact on medicines, Mankind Pharma's acquisition deal, Roche's profit forecast, EU aid for a Dutch nuclear reactor, bird flu cases, and regulatory updates on various drugs and diseases.

An Australian judge has dismissed a class action lawsuit alleging that Bayer's Roundup weedkiller causes blood cancer. The ruling, which Bayer intends to leverage in the U.S., involved over 1,000 plaintiffs linking Roundup's glyphosate to non-Hodgkins lymphoma (NHL).

The hottest day on record and frequent heat waves due to climate change are affecting medications and their efficacy for patients. Here's what you need to know about how extreme heat impacts medicines.

Indian drugmaker Mankind Pharma has announced a $1.6 billion deal to acquire Bharat Serums and Vaccines Ltd, gaining products focused on women's health and fertility treatments.

Roche has raised its 2024 profit outlook following strong demand for newer drugs like eye medicine Vabysmo, expecting high single-digit growth in adjusted earnings.

The Dutch government is poised to secure EU approval for $2.2 billion in state aid to build a nuclear reactor for medical isotopes used in cancer treatment.

Three new cases of bird flu among Colorado poultry farm workers were confirmed, bringing the total number of U.S. cases this year to 13. The workers, who experienced mild illness, are receiving antiviral treatment.

The UN's Food and Agriculture Organization has called for a rapid response to the rising spread of bird flu in humans and animals across Asia-Pacific, highlighting its unprecedented reach.

The European Medicines Agency has backed Novo Nordisk's Wegovy for lowering heart risks in overweight adults, following similar approvals from UK and U.S. regulators.

Brazil is set to announce the end of a Newcastle disease outbreak in the state of Rio Grande do Sul, according to an agriculture ministry official.

Indivior's shares surged by 22% after announcing a $100 million share buyback, driven by a 24% rise in opioid addiction treatment sales in the second quarter.

(With inputs from agencies.)